Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Towa Pharmaceutical recalls duloxetine after detection of elevated nitrosamine impurity

Towa Pharmaceutical voluntarily recalled thousands of bottles of the antidepressant duloxetine after tests found N-nitroso-duloxetine levels exceeding FDA recommended limits. The pills, distributed by Breckenridge Pharmaceutical, prompted a Class II recall due to possible increased cancer risk from prolonged exposure to nitrosamine impurities, though no direct link to cancer has been established. The FDA notes products at or below acceptable daily intake are not expected to increase cancer risk. » More on yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, TOWA PHARMA. CO. has already paid €0.22 in dividends. The last payout was in June.

Financials

In the last quarter, TOWA PHARMA. CO. had revenue of €384.55m and net profit of €29.8m

(EUR)	June 2026	YoY
Revenue	384.55m	0.05%
Gross profit	140.6m	0.67%
Net profit	29.8m	100.98%
EBITDA	62.4m	8.49%

Fundamentals

Metric	Value
Market capitalization	€986.43m
Number of shares	49.23m
52-week high/low	€25.34 - €15.60
Dividend yield	2.17%
Dividends TTM	€0.44
Next dividend	€0.22
Beta	-0.09
P/E ratio	21.14
PEG ratio	-0.44
P/B ratio	0.96
P/S ratio	0.62

Company profile

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of diabetes, digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It had a portfolio of approximately 700 drug products. Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.